Marizyme, Inc. is a medical technology company, which engages in the acquisition, development, and commercialization of therapies that minimize mortality and costs in the acute care space. The company is headquartered in Jupiter, Florida and currently employs 11 full-time employees. The firm is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Company’s product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
Follow-Up Questions
What is Marizyme Inc (MRZM)'s P/E Ratio?
The P/E ratio of Marizyme Inc is 0
Who is the CEO of Marizyme Inc?
Mr. David Barthel is the Chief Executive Officer of Marizyme Inc, joining the firm since 2021.
What is the price performance of MRZM stock?
The current price of MRZM is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Marizyme Inc?
Marizyme Inc belongs to Biotechnology industry and the sector is Health Care
